HNF1A and type 2 diabetes mellitus: The key difference in sulfonylurea treatment in neonatal diabetes is the high dose of glibenclamide required (0.45 mg/kg/day) 3 compared with the low doses in HNF1A/HNF4A MODY (<0.01 mg/kg/day) 1, 2 or typical doses in Type 2 diabetes (0.06–0.2 mg/kg/day) 32.